More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$117269356
EPS
-0.18
P/E ratio
--
Price to sales
1.99
Dividend yield
--
Beta
2.383428
Previous close
$1.06
Today's open
$1.07
Day's range
$1.04 - $1.12
52 week range
$0.90 - $2.98
show more
CEO
Alison Moore
Employees
146
Headquarters
Redwood City, CA
Exchange
Nasdaq Global Select
Shares outstanding
109597529
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
What Codexis (CDXS) Said on Its Q3 Earnings Call
Codexis NASDAQ: CDXS reported higher third-quarter revenue and a narrower loss as its pharmaceutical biocatalysis business grew, while executives outlined progress toward commercial adoption of the company's ECO Synthesis platform for manufacturing oligonucleotide medicines.
MarketBeat • Nov 13, 2026

Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 13, 2026

Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance Shared new advances in RNA therapeutic manufacturing at TIDES Europe Entered into a $60 million term loan facility with Trinity Capital; initial tranche used to refinance current debt REDWOOD CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
GlobeNewsWire • Nov 12, 2026

Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.22 per share a year ago.
Zacks Investment Research • Nov 13, 2026

Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into a $60 million senior secured term loan agreement with Trinity Capital Inc. (NYSE: TRIN), a leading provider of flexible capital solutions for life sciences and healthcare industries.
GlobeNewsWire • Nov 10, 2026

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacy
GlobeNewsWire • Nov 9, 2026

Codexis to Report Third Quarter 2026 Financial Results on November 12
REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market.
GlobeNewsWire • Oct 29, 2026

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.
GlobeNewsWire • Sep 28, 2026

Codexis to Participate in Cantor Global Healthcare Conference 2026
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.
GlobeNewsWire • Aug 27, 2026

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • Aug 14, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Codexis Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.